William Olsufka, PharmD

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

William Olsufka , PharmD;

10/26/2023

Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (Dextromethorphan-Bupropion), an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double-Blind, Controlled Trials

Abstract: Background: AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorpha...

Zachariah Thomas , DPM, AACFAS;

William Olsufka , PharmD;

01/19/2023